WHO launches global megatrial of the four most promising coronavirus treatments

@article{Kupferschmidt2020WHOLG,
  title={WHO launches global megatrial of the four most promising coronavirus treatments},
  author={Kai Kupferschmidt},
  journal={Science},
  year={2020}
}
Does lopinavir really inhibit SARS-CoV-2?
Graphical abstract
A machine learning regression model for the screening and design of potential SARS-CoV-2 protease inhibitors
TLDR
A machine learning model that can predict the binding free energies of compounds to the SARS-CoV-2 main protease is presented, which can help conserve and maximize available resources by limiting biological assays to compounds that yielded favorable outcomes from the model.
COVID-19 Clinical Trials
TLDR
This work has provided a foundation for cardiovascular and cardio-oncology physicians who are on the frontline providing care to COVID-19 patients to better understand the emerging cardiovascular epidemiology of CO VID-19, as well as the biological rationale for the clinical trials that are ongoing for the treatment of COVID -19 patients.
COVID-19 Clinical Trials
  • JACC: Basic to Translational Science
  • 2020
COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities
TLDR
The authors provide a foundation for cardiovascular and cardio-oncology physicians on the front line providing care to patients with COVID-19 to better understand the emerging cardiovascular epidemiology and the biological rationale for the clinical trials that are ongoing for the treatment of patients with CoV-19.
COVID-19 in Older People: A Rapid Clinical Review
TLDR
A rapid review of the current and emergent evidence in the COVID-19 literature is provided to form a basis on which future work can be established and suggests social distancing policies could have important negative consequences.
COVID-19: A review of the proposed pharmacological treatments
TLDR
The drug candidates that have been suggested to treat COVID-19 will be discussed and the mechanisms of action and further pharmacological properties will be explored, with a particular focus on the evidence-based safety and efficacy of each agent.
Candidate drugs against SARS-CoV-2 and COVID-19
TLDR
There exists a number of candidate drugs that may inhibit infection with and replication of SARS-CoV-2, and chloroquine and hydroxychloroquine, and off-label antiviral drugs, such as the nucleotide analogue remdesivir, HIV protease inhibitors lopinavir and ritonavir, broad-spectrum antiviral Drugs arbidol and favipiravir as well as antiviral phytochemicals available to date may prevent spread.
Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today's battle against COVID-19?
TLDR
It is hypothesize that CQ/HCQ plus zinc supplementation may be more effective in reducing COVID-19 morbidity and mortality than CQ or HCQ in monotherapy and should be considered as additional study arm for CO VID-19 clinical trials.
Efficacy and Safety of Remdesivir in COVID-19 Patients: A Retrospective Analysis of Active Surveillance Database
TLDR
The analysis showed that remdesivir is well tolerated and has an acceptable safety profile, and that the mortality rate was significantly lower in patients < 60 years old than in those >60 years old, and amongst patients on oxygen therapy, the cure/improvement rate was higher in those receiving standard low-flow oxygen.
...
1
2
3
4
5
...